Zafgen stakes out a PhI beachhead for its next weight drug as it fights for a comeback
Last summer Zafgen $ZFGN experienced one of the worst biotech disasters the industry witnessed for all of last year — the kind of nightmare that CEOs dread. After the FDA put their lead drug beloranib on clinical hold in late 2015 — linking it to the death of a patient from a pulmonary embolism linked with the therapy — the biotech had little choice but to kill the program in July and slash its staff after regulators spelled out what they would have to do to qualify for a marketing OK.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
